If you’re not a man in the market for a natural way to boost your sexual performance, you may be unfamiliar with yohimbe. It’s an African tree whose bark yields a substance, yohimbine, which can be extracted and used as an aphrodisiac.
But for those who seek this common supplement, beware: according to a new study by Harvard researchers, the vast majority of yohimbe sold as a dietary supplement by mainstream retailers in the U.S. is mislabeled in a way that could pose a safety risk to consumers.
Dr. Pieter Cohen, an assistant professor at Harvard Medical School who studies dietary supplements, says of the 49 yohimbe products he and his colleagues tested, most had inaccurate data either about the quantity of active ingredient or an incomplete list of known side effects.
“These are completely misleading in terms of labels,” Cohen, the lead author of the new study and an internist at Cambridge Health Alliance, said in an interview. “If safe consumption of a product requires that both accurate quantity as well as known adverse effects be provided on the label, then only 4.1 percent of the yohimbine supplement brands analyzed provided sufficient safety information for consumers.”
But the real problem, Cohen says, is the federal law governing dietary supplements which regulates such products more like food than drugs and doesn’t require the kind of stringent pre-market testing for safety and effectiveness mandated for prescription drugs. “Every problem we found with yohimbe supplements brings us back to fundamental flaws in the law,” Cohen said.
Here’s the conclusion of his study, published today in the journal Drug Testing and Analysis: Continue reading